Rapid Micro Biosystems, Inc. (RPID) Stock Price & Analysis
Rapid Micro Biosystems, Inc. (RPID) fell 5.07% to USD 1.31 as of September 8, 2026 at 05:51 UTC, according to Nexqual real-time market data.
RPID last closed at USD 1.31; the session ranged USD 1.29–1.49 on volume of 378,832 shares. Market capitalization is —, with a 52-week range of USD 1.29–4.94 (NCM). Source: Nexqual, September 8, 2026 at 05:51 UTC.
Key Statistics (as of September 8, 2026 at 05:51 UTC)
| Price | USD 1.31 |
|---|---|
| Change | ▼ 5.07% (down) |
| Previous Close | USD 1.31 |
| Open | USD 1.31 |
| Day Range | USD 1.29 – 1.49 |
| 52-Week Range | USD 1.29 – 4.94 |
| Volume | 378,832 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (RPID)
Nexqual's technical model rates RPID "SELL" based on 3 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 05:51 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 19.29 (oversold) |
| vs SMA50 | Below (USD 1.81) |
| MACD | -0.13 (negative) |
From Rapid Micro Biosystems, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Through our unique expertise at the intersection of microbiology, robotic systems, and advanced vision algorithms, we are setting the foundation for end-to-end quality control automation to enable the future of advanced pharmaceutical manufacturing.
- Our proprietary technology works by replacing human counting of growing colonies with software and algorithm detection and counting based on image analysis.
- Drive new customer adoption of the Growth Direct platform by converting the leading manufacturers in our core markets, including top 50 pharmaceutical companies and leading CDMOs — There are 49 global customers that have adopted the Growth Direct platform to automate MQC testing in 107 manufacturing facilities.
- Our platform comprises the Growth Direct system, proprietary consumables, lab information management system ("LIMS") connection and other software, and comprehensive customer support and validation services.
Partnerships
- We originally developed our platform in close collaboration with our customers, and our customers' success in validating our technology constitutes a major driver for platform deployment.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SGHT | Sight Sciences, Inc. | USD 8.35 | ▼ 0.83% |
| CTKB | Cytek Biosciences, Inc. | USD 4.7 | ▲ 0.21% |
| AIRS | AirSculpt Technologies, Inc. | USD 2.8 | ▲ 13.62% |
| TMCI | Treace Medical Concepts, Inc. | USD 4.81 | ▲ 2.34% |
| DSGN | Design Therapeutics, Inc. | USD 15.14 | ▼ 2.51% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:51 UTC. This page is informational and not investment advice.